Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110223 | 0.93 | ALDH1A1 (0.46) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 | |
| SCHEMBL579460 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 | |
| SCHEMBL5665047 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL15927526 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 | |
| SCHEMBL1655486 | 0.80 | LMNA (0.38) | ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL16273723 | 0.80 | HDAC1 (0.43) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 | |
| SCHEMBL10340549 | 0.80 | LMNA (0.51) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 | |
| SCHEMBL19426340 | 0.79 | HDAC1 (0.44) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 | |
| SCHEMBL15927536 | 0.79 | ALDH1A1 (0.47) | ALDH1A1HDAC1HDAC2KMT2AMAPT | |
| SCHEMBL10830571 | 0.78 | EHMT2 (0.43) | ALDH1A1HDAC1HDAC2SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056069-A1 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| EP-4126042-A2 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Angiex, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021195598-A2 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| EP-3271401-A1 | CONJUGATES FOR THE TREATMENT OF CANCER TARGETED AT INTRACELLULAR TUMOR-ASSOCIATED ANTIGENS | Immunobiochem Corporation (CA) | 2018-01-24 | — | — | EP | claimed |
| EP-3218410-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2017-09-20 | — | — | EP | claimed |
| WO-2016145536-A1 | CONJUGATES FOR THE TREATMENT OF CANCER TARGETED AT INTRACELLULAR TUMOR-ASSOCIATED ANTIGENS | IMMUNOBIOCHEM CORPORATION (CA) | 2016-09-22 | — | — | WO | claimed |
| WO-2016075670-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2016-05-19 | — | — | WO | claimed |
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | Cybrexa 3, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. | 2024-02-29 | — | — | US | disclosed |
| EP-4326316-A1 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES BEARING TGF-BETA AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4291233-A1 | POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE | Wugen, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023137156-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137158-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2010126551-A1 | POTENT CONJUGATES AND HYDROPHILIC LINKERS | IMMUNOGEN, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-2238168-A1 | AGENTS TARGETING CD138 AND USES THEREOF | Biotest AG (DE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009134976-A1 | POTENT CONJUGATES AND HYDROPHILIC LINKERS | IMMUNOGEN, INC (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134952-A2 | POTENT CONJUGATES AND HYDROPHILIC LINKERS | IMMUNOGEN, INC (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009080829-A1 | AGENTS TARGETING CD138 AND USES THEREOF | BIOTEST AG (DE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1928503-A2 | PROCESS FOR PREPARING MAYTANSINOID ANTIBODY CONJUGATES | IMMUNOGEN INC (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007024536-A2 | PROCESS FOR PREPARING MAYTANSINOID ANTIBODY CONJUGATES | IMMUNOGEN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | MAP4, MAP2, TUBB3 | ALDH1A1 4001/4885HDAC1 2122/4885HDAC2 3505/4885 |
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | MAP4, MAP2, TUBB3 | ALDH1A1 4001/4885HDAC1 2122/4885HDAC2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.